Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 19981-19990 Newer>

The Motley Fool January 22, 2007 Emil Lee	The Buffett Common Denominator It's not hard to identify great advertising when you see it. Investors might want to keep these advertisers in mind when identifying which companies to invest in. Procter & Gamble... Berkshire... American Express... etc.
The Motley Fool January 22, 2007 Rich Smith	Foolish Forecast: Testing Teradyne When the semiconductor tester arrives on Wall Street with its fourth-quarter and full-year 2006 results, will the firm continue its streak of trumping expectations? Investors, take note.
The Motley Fool January 22, 2007 Anders Bylund	Foolish Forecast: AMD Slugs It Out The chip maker is set to report earnings for the full year and fourth quarter of fiscal 2006. Investors, do you want to know what Wall Street expects to see? Do you want to know what really matters?
The Motley Fool January 22, 2007 Rich Duprey	Sharper Image Cuts a Deal The retailer settles a class action lawsuit, which might end up boosting its sales. Investors, take note.
The Motley Fool January 22, 2007 Anders Bylund	Foolish Forecast: Tackling Texas Instruments Here's the latest earnings lowdown from the broad-line chip maker. Investors in the semiconductor sector are watching for signs of weakness or strength from this bellwether.
The Motley Fool January 22, 2007 Ryan Fuhrmann	Regions Financial Stays Close to Home Investors, it's time to keep an eye on this active banking-industry player.
The Motley Fool January 22, 2007 Jack Uldrich	Solar Power Goes to Washington Solar power's success in lobbying Congress could benefit investors.
The Motley Fool January 22, 2007 S.J. Caplan	Scouting the Latest IPOs An investor's roundup of new-issue hits, misses, and no-shows: AeroVironment... Converted Organics... Meruelo Maddux Properties... Oculus Innovative Sciences... etc.
The Motley Fool January 22, 2007 Brian Lawler	QLT's Sagging Sales The drug developer's macular degeneration treatment has seen declining sales. And as sales fall, so too does the percent of profits that QLT keeps. Investors, take note.
The Motley Fool January 22, 2007 David Lee Smith	Where to Now, Tribune? Tribune's share price, which began 2004 above $51, closed Friday at $30.52. A cynic might blame Tribune's mounting woes and inability to sell itself for a reasonable price on its Cubs ownership.
<Older 19981-19990 Newer> Return to current articles.